Israel Englander Abb Vie Inc. Transaction History

Millennium Management LLC

$224 Billion
Q1 2024

A detailed history of Israel Englander (Millennium Management LLC) transactions in Abb Vie Inc. stock. As of the latest transaction made, Millennium Management LLC holds 948,000 shares of ABBV stock, worth $153 Million. This represents 0.08% of its overall portfolio holdings.

Number of Shares

948,000

Previous 1,036,400 8.53%

Holding current value

$153 Million

Previous $161 Million 7.48%

% of portfolio

0.08%

Previous 0.07%

26 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2024 May 15, 2024	SELL	$159.82 - $182.1 $105 Million - $120 Million	-657,764 Reduced 83.99%	125,386 $22.8 Million
Q4 2023 Feb 14, 2024	SELL	$137.6 - $154.97 $45.1 Million - $50.8 Million	-327,790 Reduced 29.51%	783,150 $121 Million
Q2 2023 Aug 14, 2023	BUY	$132.51 - $164.9 $22.7 Million - $28.3 Million	171,401 Added 18.24%	1,110,940 $150 Million
Q1 2023 May 15, 2023	BUY	$144.61 - $166.54 $117 Million - $134 Million	807,485 Added 611.48%	939,539 $150 Million
Q4 2022 Feb 14, 2023	SELL	$138.31 - $165.87 $69.9 Million - $83.8 Million	-505,224 Reduced 79.28%	132,054 $21.3 Million

Q3 2022 Nov 14, 2022	BUY	$134.21 - $153.93 $73.6 Million - $84.4 Million	548,224 Added 615.61%	637,278 $85.5 Million
Q2 2022 Aug 15, 2022	SELL	$137.62 - $174.96 $49.9 Million - $63.5 Million	-362,772 Reduced 80.29%	89,054 $13.6 Million
Q1 2022 May 16, 2022	SELL	$131.98 - $163.75 $55.7 Million - $69.1 Million	-422,005 Reduced 48.29%	451,826 $73.2 Million
Q4 2021 Feb 14, 2022	BUY	$107.43 - $135.93 $25 Million - $31.6 Million	232,675 Added 36.29%	873,831 $118 Million
Q3 2021 Nov 15, 2021	SELL	$106.4 - $120.78 $38.4 Million - $43.6 Million	-361,369 Reduced 36.05%	641,156 $69.2 Million
Q2 2021 Aug 16, 2021	BUY	$105.21 - $117.21 $102 Million - $114 Million	973,668 Added 3374.11%	1,002,525 $113 Million
Q1 2021 May 17, 2021	SELL	$102.3 - $112.62 $9.35 Million - $10.3 Million	-91,395 Reduced 76.0%	28,857 $3.12 Million
Q4 2020 Feb 16, 2021	SELL	$80.49 - $108.67 $3.51 Million - $4.73 Million	-43,572 Reduced 26.6%	120,252 $12.9 Million
Q3 2020 Nov 16, 2020	SELL	$85.91 - $100.83 $60.6 Million - $71.1 Million	-705,346 Reduced 81.15%	163,824 $14.3 Million
Q2 2020 Aug 14, 2020	BUY	$73.37 - $98.18 $7.55 Million - $10.1 Million	102,886 Added 13.43%	869,170 $85.3 Million
Q1 2020 May 14, 2020	SELL	$64.5 - $97.79 $62,500 - $94,758	-969 Reduced 0.13%	766,284 $58.4 Million
Q4 2019 Feb 14, 2020	BUY	$72.13 - $90.25 $47.9 Million - $59.9 Million	663,952 Added 642.74%	767,253 $67.9 Million
Q3 2019 Nov 14, 2019	SELL	$62.98 - $75.72 $43.3 Million - $52.1 Million	-687,799 Reduced 86.94%	103,301 $7.82 Million
Q2 2019 Aug 15, 2019	BUY	$65.7 - $83.98 $47.6 Million - $60.9 Million	724,775 Added 1092.76%	791,100 $57.5 Million
Q2 2019 Aug 14, 2019	SELL	$65.7 - $83.98 $22.9 Million - $29.3 Million	-348,498 Reduced 84.01%	66,325 $830,000
Q1 2019 May 14, 2019	SELL	$77.14 - $90.79 $94.2 Million - $111 Million	-1,220,553 Reduced 74.63%	414,823 $33.4 Million
Q3 2018 Nov 14, 2018	SELL	$88.91 - $98.84 $95.6 Million - $106 Million	-1,075,736 Reduced 39.68%	1,635,376 $155 Million
Q2 2018 Aug 14, 2018	BUY	$89.78 - $106.23 $167 Million - $198 Million	1,864,703 Added 220.31%	2,711,112 $251 Million
Q1 2018 May 15, 2018	BUY	$92.01 - $123.21 $52.6 Million - $70.5 Million	572,179 Added 208.65%	846,409 $80.1 Million
Q4 2017 Feb 14, 2018	SELL	$89.56 - $98.21 $20 Million - $21.9 Million	-222,855 Reduced 44.83%	274,230 $26.5 Million
Q3 2017 Nov 14, 2017	BUY	$69.85 - $89.22 $34.7 Million - $44.3 Million	497,085	497,085 $44.2 Million

Others Institutions Holding ABBV

# of Institutions

3,643

Shares Held

1.24B

Call Options Held

15.5M

Put Options Held

11.6M

View Full List

About AbbVie Inc.

Ticker ABBV
Exchange NYSE
Sector Healthcare
Industry Drug Manufacturers—General
Shares Outstandng 1,768,099,968
Market Cap $285B
Description
AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals in the worldwide. The company offers HUMIRA, a therapy administered as an injection for autoimmune and intestinal Behçet's diseases; SKYRIZI to treat moderate to severe plaque psoriasis in adults; RINVOQ, a JAK inhibitor for the treatment of moderate to severe active rheuma...

More about ABBV

Track Israel Englander's Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Millennium Management LLC, based on Form 13F filings with the SEC.

News

Stay updated on Millennium Management LLC and Israel Englander with notifications on news.

Account